Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

Go back to Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
(NASDAQ: TVTX) Delayed: 55.15 --0 (-0%)
Previous Close $55.15    52 Week High
Open $55.15    52 Week Low
Day High $55.15    P/E N/A 
Day Low $55.15    EPS
Volume 2,215